

TTF-1 [SPT24]

Concentrated and Prediluted Monoclonal Antibody
902-3126-091917

BIOCARE
M E D I C A L

Catalog Number:	ACR 3126 A, C	APR 3126 AA
Description:	0.1, 1.0 ml concentrated	6.0 ml, prediluted
Dilution:	1:100	Ready-to-use
Diluent:	Renoir Red	N/A

Intended Use:

For Research Use Only. Not for use in diagnostic procedures.

Summary and Explanation:

Thyroid transcription factor-1 (TTF-1) is a 38 kDa member of the NKX2 family of homeodomain transcription factors. TTF-1 is mostly detected in primary lung adenocarcinomas and small cell carcinomas (1). TTF-1 can be very useful in lung cancers when used in a panel with Desmoglein 3, p40 and Napsin A antibodies (2-3).

Commercially available thyroid transcription factor-1 (TTF-1) monoclonal antibodies 8G7G3/1 and SPT24 have been shown to have different sensitivities in lung adenocarcinomas (LADC) and lung squamous cell carcinomas (SqCC) (4-6). A study by Masai, *et al.* demonstrated that SPT24 was much more sensitive than 8G7G3/1 in LADC (72.4% and 65.4% respectively). However, the study demonstrated that SPT24 stained a higher percentage of lung SqCC (16.8% vs. 1%). Higher sensitivity of SPT24 in lung SqCC has also been shown to be heavily influenced by different detection systems (4-5).

Higher sensitivity for LADC versus lung SqCC can be achieved with SPT24, compared to 8G7G3/1, while retaining specificity, by the use of a cut-off value and optimal antibody titer. In an in-house study, SPT24 was titrated to achieve negative staining in normal liver (no cytoplasmic staining observed). A cut-off value of $\geq 10\%$ of tumor cells positive for TTF-1 with a staining intensity of $\geq 1+$ was used to identify TTF-1 positive cases. Using this approach, SPT24 was highly sensitive for LADC (53/60, 88%), compared to 8G7G3/1 (38/60, 63%), with equivalent specificity for both clones versus lung SqCC (2/137, 1.5%). Use of lung SqCC specific markers, such as Desmoglein 3 and p40, may identify TTF-1 positive cases of squamous cell origin. Additionally, the use of Napsin A may confirm lung adenocarcinoma as the co-expression of Napsin A and TTF-1 in lung cancers has been shown to be more pulmonary specific than either one used alone (7). Finally, unlike clone 8G7G3/1, no cytoplasmic staining in lung cancers has been observed with clone SPT24 (8).

Principle of Procedure:

Antigen detection in tissues and cells is a multi-step immunohistochemical process. The initial step binds the primary antibody to its specific epitope. A secondary antibody may be applied to bind the primary antibody, followed by an enzyme labeled polymer; or an enzyme labeled polymer may be applied directly to bind the primary antibody. The detection of the bound primary antibody is evidenced by an enzyme-mediated colorimetric reaction.

Source: Mouse monoclonal

Species Reactivity: Human; others not tested

Clone: SPT24

Isotype: IgG1/kappa

Total Protein Concentration: ~10 mg/ml. Call for lot specific Ig concentration.

Epitope/Antigen: TTF-1 (Thyroid transcription factor-1)

Cellular Localization: Nuclear

Positive Tissue Control: Lung adenocarcinoma

Negative Tissue Control: Normal liver, lung squamous cell carcinoma

Known Applications:

Immunohistochemistry (formalin-fixed paraffin-embedded tissues)

Supplied As: Buffer with protein carrier and preservative

Storage and Stability:

Store at 2°C to 8°C. Do not use after expiration date printed on vial. If reagents are stored under conditions other than those specified in the package insert, they must be verified by the user. Diluted reagents should be used promptly; any remaining reagent should be stored at 2°C to 8°C.

Staining Protocol Recommendations:

Peroxide Block: Block for 5 minutes with Biocare's Peroxidized 1.

Pretreatment: Perform heat retrieval using Biocare's Diva Decloaker. Refer to the Diva Decloaker data sheet for specific instructions.

Protein Block (Optional): Incubate for 5-10 minutes at RT with Biocare's Background Punisher.

Primary Antibody: Incubate for 30 minutes at RT.

Probe: Incubate for 10 minutes at RT with a secondary probe.

Polymer: Incubate for 10-20 minutes at RT with a tertiary polymer.

Chromogen: Incubate for 5 minutes at RT with Biocare's DAB – OR – Incubate for 5-7 minutes at RT with Biocare's Warp Red.

Counterstain:

Counterstain with hematoxylin. Rinse with deionized water. Apply Tacha's Bluing Solution for 1 minute. Rinse with deionized water.

Technical Note:

This antibody has been standardized with Biocare's MACH 4 detection system. Use TBS buffer for washing steps.

Limitations:

This product is provided for Research Use Only (RUO) and is not for use in diagnostic procedures. Suitability for specific applications may vary and it is the responsibility of the end user to determine the appropriate application for its use.

Precautions:

1. This antibody contains less than 0.1% sodium azide. Concentrations less than 0.1% are not reportable hazardous materials according to U.S. 29 CFR 1910.1200, OSHA Hazard communication and EC Directive 91/155/EC. Sodium azide (Na₃) used as a preservative is toxic if ingested. Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. Upon disposal, flush with large volumes of water to prevent azide build-up in plumbing. (Center for Disease Control, 1976, National Institute of Occupational Safety and Health, 1976) (9)

2. Specimens, before and after fixation, and all materials exposed to them should be handled as if capable of transmitting infection and disposed of with proper precautions. Never pipette reagents by mouth and avoid contacting the skin and mucous membranes with reagents and specimens. If reagents or specimens come in contact with sensitive areas, wash with copious amounts of water. (10)

3. Microbial contamination of reagents may result in an increase in nonspecific staining.

4. Incubation times or temperatures other than those specified may give erroneous results. The user must validate any such change.

5. Do not use reagent after the expiration date printed on the vial.

6. The SDS is available upon request and is located at <http://biocare.net>.

Technical Support:

Contact Biocare's Technical Support at 1-800-542-2002 for questions regarding this product.



60 Berry Drive
Pacheco, CA 94553
USA

Rev: 062117

Tel: 800-799-9499 | www.biocare.net | Fax: 925-603-8080

TTF-1 [SPT24]

Concentrated and Prediluted Monoclonal Antibody
902-3126-091917

BIOCARE
M E D I C A L

References:

1. Di Loreto C, *et al.* Immunocytochemical expression of tissue specific transcription factor-1 in lung carcinoma. *J Clin Pathol.* 1997 Jan; 50(1):30-2.
2. Tacha D, *et al.* A 6-antibody panel for the classification of lung adenocarcinoma versus squamous cell carcinoma. *Appl Immunohistochem Mol Morphol.* 2012 May; 20 (3):201-7.
3. Brown AF, *et al.* Tissue-preserving antibody cocktails to differentiate primary squamous cell carcinoma, adenocarcinoma, and small cell carcinoma of lung. *Arch Pathol Lab Med.* 2013 Sep; 137(9):1274-81.
4. Masai K, *et al.* Expression of squamous cell carcinoma markers and adenocarcinoma markers in primary pulmonary neuroendocrine carcinomas. *Appl Immunohistochem Mol Morphol.* 2013 Jul; 21(4):292-7.
5. Matoso A, *et al.* Comparison of thyroid transcription factor-1 expression by 2 monoclonal antibodies in pulmonary and nonpulmonary primary tumors. *Appl Immunohistochem Mol Morphol.* 2010 Mar; 18(2):142-9.
6. Ordóñez NG. Value of thyroid transcription factor-1 immunostaining in tumor diagnosis: a review and update. *Appl Immunohistochem Mol Morphol.* 2012 Oct; 20 (5):429-44.
7. Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. *Hum Pathol.* 2010 Jan; 41(1):20-5.
8. Bejarano PA, Mousavi F. Incidence and significance of cytoplasmic thyroid transcription factor-1 immunoreactivity. *Arch Pathol Lab Med.* 2003 Feb; 127(2):193-5.
9. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 "Decontamination of Laboratory Sink Drains to Remove Azide Salts."
10. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.



60 Berry Drive
Pacheco, CA 94553
USA

Rev: 062117

Tel: 800-799-9499 | www.biocare.net | Fax: 925-603-8080